In vitro assay for quantifying clostridial neurotoxin activity

Patent metadata

Field	Value
Publication number	US-9310386-B2
Application number	US-201113574113-A
Country	US
Kind code	B2
Filing date	Jan 19, 2011
Priority date	Jan 22, 2010
Publication date	Apr 12, 2016
Grant date	Apr 12, 2016

Abstract

Novel methods for determining the unknown biological activity of a clostridial neurotoxin in a sample with respect to the known biological activity of a clostridial neurotoxin in a reference sample, comprising the step of comparing the biological activity of a clostridial neurotoxin preparation with the biological activity of a standard preparation of a reference clostridial neurotoxin in certain in vitro systems.

First claim

The invention claimed is:

1. An in vitro method for determining the biological activity of a preparation of a clostridial neurotoxin, comprising the steps of:
(a) contacting at least one test particle with a sample of the clostridial neurotoxin preparation;
(b) measuring one or more parameters selected from time-dependent decrease of an amount of unchanged starting substrate within the test particle, time-dependent increase of an amount of one or more cleavage products resulting from proteolytic cleavage of a substrate within the test particle, time-dependent decrease of an amount of a compound released from the test particle; and
(c) comparing the measurement of the parameter in step (b) of the sample of the clostridial neurotoxin preparation with the measurement of the parameter in step (b) of a reference sample, thereby determining the amount of the biological activity of the clostridial neurotoxin in the preparation;

wherein the at least one test particle comprises at least a membrane enclosing a reaction volume, wherein the membrane carries one or more clostridial neurotoxin receptors which bind the clostridial neurotoxin and mediate internalization of the clostridial neurotoxin into the reaction volume, and wherein the reaction volume comprises a substrate for clostridial neurotoxin which is proteolytically cleaved by the clostridial neurotoxin in the reaction volume of the test particle.

2. The method of claim 1 , further comprising after step (a), a step of:
(aa) adjusting the medium surrounding said teat particle by decreasing the pH value.

3. The method of claim 1 , further comprising after step (a), a step of:
(ab) adjusting the reaction volume in the test particle by decreasing the pH value; and/or
(ac) adjusting the reaction volume in the test particle by increasing the reducing potential.

4. The method of claim 1 , wherein step (b) comprises a step of:
(ba) determining binding of the clostridial neurotoxin to the one or more receptors.

5. The method of claim 1 , wherein the proteolytic cleavage of a substrate is determined by Enzyme-Linked Immunosorbent Assay (ELISA) or fluorometric measurement of botulinum toxin activity on a fluorescently labeled synaptosomal-associated protein 25 kDa (SNAP-25)-based substrate containing the native cleavage site for botulinum neurotoxin of serotype A or serotype E.

6. The method of claim 1 , wherein the test particle is a non-cellular test particle.

7. The method of claim 6 , wherein the non-cellular test particle is a synaptosome.

8. The method of claim 6 , wherein the non-cellular test particle is an artificially generated particle.

9. The method of claim 1 , wherein the clostridial neurotoxin is a Clostridium botulinum neurotoxin of serotype A, B, C1, D, E, F or G, or is a biologically active derivative thereof.

10. The method of claim 9 , wherein the clostridial neurotoxin of serotype A or E, or is a biologically active derivative thereof.

11. The method of claim 10 , wherein the clostridial neurotoxin is of serotype A, and wherein one or more receptors on the membrane are selected from synaptic vesicle protein 2 (SV2), a ganglioside receptor, a biologically active derivative of SV2, and combinations thereof.

12. The method of claim 11 , wherein the ganglioside receptor is selected from GT1b and GD1b.

13. The method claim 1 , wherein the substrate is synaptosomal-associated protein 25 kDa (SNAP-25) or a biologically active variant thereof.

14. A kit for determining the biological activity of a preparation of a clostridial neurotoxin comprising:
(a) at least one test particle comprising at least a membrane enclosing a reaction volume, wherein the membrane carries one or more clostridial neurotoxin receptors which bind the clostridial neurotoxin and mediate internalization of the clostridial neurotoxin into the reaction volume, and wherein the reaction volume comprises a substrate for clostridial neurotoxin which is proteolytically cleaved by the clostridial neurotoxin in the reaction volume of the test particle;
(b) one or more reagents for determining binding of the clostridial neurotoxin to the one or more receptors; and/or
(c) one or more reagents for determining proteolytic cleavage of the substrate.

Assignees

• Wilk Thomas
• Taylor Harold Victor
• Eisele Karl-Heinz
• Merz Pharma Gmbh & Co Kgaa

Inventors

• Wilk Thomas
• Taylor Harold Victor
• Eisele Karl-Heinz

Classifications

• G01N33/94 Primary

  involving narcotics {or drugs or pharmaceuticals, neurotransmitters or associated receptors} · CPC title

• C12Q1/37

  involving peptidase or proteinase · CPC title

• G01N2333/33

  from Clostridium (G) · CPC title